1062 related articles for article (PubMed ID: 24189279)
41. Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.
Ash MM; Jolly PS
Int J Dermatol; 2015 Mar; 54(3):370-4. PubMed ID: 25039741
[TBL] [Abstract][Full Text] [Related]
42. Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study.
Hansson J; Bartley K; Karagiannis T; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Yim YM; Dimier N; Fittipaldo A; Basset-Séguin N; Hauschild A
Eur J Dermatol; 2018 Dec; 28(6):775-783. PubMed ID: 30698147
[TBL] [Abstract][Full Text] [Related]
43. [Vismodegib in metastasized basal cell carcinoma].
Reinders MG; Dirix L; Mosterd K; van Doorn R
Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
[TBL] [Abstract][Full Text] [Related]
44. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.
Bhutani T; Abrouk M; Sima CS; Sadetsky N; Hou J; Caro I; Chren MM; Arron ST
J Am Acad Dermatol; 2017 Oct; 77(4):713-718. PubMed ID: 28780365
[TBL] [Abstract][Full Text] [Related]
45. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.
Sekulic A; Yoo S; Kudchadkar R; Guillen J; Rogers G; Chang ALS; Guenthner S; Raskin B; Dawson K; Mun Y; Chu L; McKenna E; Lacouture M
PLoS One; 2022; 17(1):e0262151. PubMed ID: 35030185
[TBL] [Abstract][Full Text] [Related]
46. Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach.
Rodríguez-Cerdeira C; Muñoz-Garzón V; González-Cespón JL
Drug Discov Ther; 2019; 13(2):122-127. PubMed ID: 31080204
[TBL] [Abstract][Full Text] [Related]
47. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
Danial C; Sarin KY; Oro AE; Chang AL
Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
[TBL] [Abstract][Full Text] [Related]
48. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.
Dréno B; Kunstfeld R; Hauschild A; Fosko S; Zloty D; Labeille B; Grob JJ; Puig S; Gilberg F; Bergström D; Page DR; Rogers G; Schadendorf D
Lancet Oncol; 2017 Mar; 18(3):404-412. PubMed ID: 28188086
[TBL] [Abstract][Full Text] [Related]
49. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
Demirci H; Worden F; Nelson CC; Elner VM; Kahana A
Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162
[TBL] [Abstract][Full Text] [Related]
51. Vismodegib, a hedgehog pathway inhibitor for adults with locally advanced or metastatic basal cell carcinoma.
Wilkes GM
Oncology (Williston Park); 2012 Aug; 26(8 Suppl Nurse Ed):31-3. PubMed ID: 25375009
[No Abstract] [Full Text] [Related]
52. Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.
Calzavara Pinton P; Licitra L; Peris K; Santoro A; Ascierto PA
Future Oncol; 2015; 11(9):1429-35. PubMed ID: 25952787
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of Vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities.
Spallone G; Sollena P; Ventura A; Fargnoli MC; Gutierrez C; Piccerillo A; Tambone S; Bianchi L; Peris K
Dermatol Ther; 2019 Nov; 32(6):e13108. PubMed ID: 31606940
[TBL] [Abstract][Full Text] [Related]
54. Identifying patients at risk for recurrent or advanced BCC.
Hamid O; Goldenberg G
J Drugs Dermatol; 2013 Nov; 12(11):1246-52; quiz 1253-4. PubMed ID: 24196332
[TBL] [Abstract][Full Text] [Related]
55. Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.
Soura E; Plaka M; Dessinioti C; Chasapi V; Stefanaki C; Antoniou C; Stratigos A
Pediatr Dermatol; 2018 Nov; 35(6):e334-e336. PubMed ID: 30178564
[TBL] [Abstract][Full Text] [Related]
56. Vismodegib.
Meiss F; Zeiser R
Recent Results Cancer Res; 2014; 201():405-17. PubMed ID: 24756807
[TBL] [Abstract][Full Text] [Related]
57. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.
Saintes C; Saint-Jean M; Brocard A; Peuvrel L; Renaut JJ; Khammari A; Quéreux G; Dréno B
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1006-9. PubMed ID: 24980899
[TBL] [Abstract][Full Text] [Related]
58. Vismodegib in basal cell carcinoma.
Amaria RN; Bowles DW; Lewis KD; Jimeno A
Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
[TBL] [Abstract][Full Text] [Related]
59. Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.
Fife K; Herd R; Lalondrelle S; Plummer R; Strong A; Jones S; Lear JT
Future Oncol; 2017 Jan; 13(2):175-184. PubMed ID: 27640448
[TBL] [Abstract][Full Text] [Related]
60. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma.
Mohan SV; Chang J; Li S; Henry AS; Wood DJ; Chang AL
JAMA Dermatol; 2016 May; 152(5):527-32. PubMed ID: 26914338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
